Table 1 Physicochemical guidelines for designing macrocyclic drugs (Villar et al.14).

From: Cutting-edge Bioinformatics strategies for synthesizing Cyclotriazadisulfonamide (CADA) analogs in next-Generation HIV therapies

Property

Conventional drugs

Oral macrocyclic drugs

Non-oral macrocyclic drugs

MolW

\(\:\le\:\) 500

600–1200

600–1300

clogP

\(\:\le\:\) 5

-2 to 6

-7 to 2

PSA

\(\:\le\:\) 140 Å2

180–320 Å2

150–500 Å2

No. of HBDs

\(\:\le\:\) 5

\(\:\le\:\) 12

\(\:\le\:\) 17

No. of HBAs

\(\:\le\:\) 10

12–16

9–20

NRB value

\(\:\le\:\) 10

\(\:\le\:\) 15

\(\:\le\:\) 30